DALLAS, TX and NEW YORK, NY--(Marketwired - May 27, 2015) - PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, announces today that they will be presenting at the 2015 Marcum MicroCap Conference. Management is available throughout the conference for the one-on-one meetings as well.
Event: Marcum MicroCap Conference
Date: Thursday, May 28th, 2015
Time: 11:00 am EST
Location: Alvin Room - Conference Foyer at the Grand Hyatt Hotel, New York City
The presentation will be open to all interested investors through a live audio webcast accessible from http://wsw.com/webcast/marcum3/ptbi. An archived replay of the webcast will also be available for 30 days following the live presentation.
The Marcum MicroCap Conference is dedicated to providing a forum where publicly traded companies under $500 million in market capitalization can network with the investment community.
About PlasmaTech Biopharmaceuticals: PlasmaTech Biopharmaceuticals is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. PlasmaTech's lead program is a gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. In addition, the company is pursuing two additional proprietary platforms, Salt Diafiltration (SDF™) Process and Polymer Hydrogel Technology (PHT™), and is active in the development and commercialization of human plasma-derived therapeutics, including its proprietary alpha-1 protease inhibitor, SDF Alpha™. The company has developed a robust product pipeline that includes two commercial stage products, MuGard® and ProctiGard™, with additional follow-on products in development. Please click here for more information on Abeona Therapeutics: http://abeonatherapeutics.com/
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, those relating to: the Company's acquisition of Abeona, anticipated acceleration in the development and internationalization of clinical programs, information regarding the future performance of the combined company, the outlook on medical needs, future pipeline expectations, management plans for the Company, the anticipated closing of the transaction, and general business outlook. These statements are subject to numerous risks and uncertainties, including but not limited the satisfaction of closing conditions for the transaction, the parties' ability to successfully integrate and operate the new company, and achieve expected synergies and other benefits; the impact of competition; the ability to develop products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.
Company and Media Contact:
Director of Communications
PlasmaTech Biopharmaceuticals, Inc.